All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

@so.dreamie's Wegovy first shot documentation, fact-checked

ShortCakkes

TikTok creator

300.1K viewsWatch on TikTok→

Quick answer

Wegovy contains semaglutide, a GLP-1 receptor agonist that slows gastric emptying and reduces appetite. In the STEP 1 trial, participants lost an average of 14.9% body weight over 68 weeks with the 2.4mg maintenance dose.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

@so.dreamie posted a 300K-view TikTok documenting her first Wegovy injection, claiming it made a "huge difference." While she's right that documenting your progress can be helpful, there's more context people need about what to expect from their first shots.

What does this video actually show?

The creator shows herself taking what she says is her first Wegovy injection and claims she can already see a "huge difference." She's encouraging others in the "GLP1 TikTok family" to notice her progress.

The video appears to be genuine documentation of someone starting semaglutide treatment. She mentions it was recorded on her iPad and forgotten about, which suggests this wasn't originally planned for social media.

However, the timeline here matters a lot. Wegovy doesn't work like flipping a switch, and any dramatic changes visible immediately after a first injection would be concerning rather than encouraging.

What should you expect from your first Wegovy shot?

Your first Wegovy injection won't produce visible weight loss within days or weeks. The STEP 1 trial (Wilding et al., NEJM, 2021) showed that participants lost an average of 14.9% of their body weight, but this happened over 68 weeks, not days.

The first injection contains just 0.25mg of semaglutide. This starting dose exists primarily to help your body adjust to the medication and minimize side effects like nausea and vomiting.

You'll gradually increase to 0.5mg, then 1mg, 1.7mg, and finally the maintenance dose of 2.4mg over 16-20 weeks. Most people don't see significant weight changes until they reach higher doses months into treatment.

Could she really see a "huge difference" this early?

Any dramatic visual changes after a first Wegovy shot would likely be water weight or placebo effect, not fat loss. Semaglutide works by slowing gastric emptying and affecting appetite hormones, but these mechanisms take time to produce measurable weight loss.

The STEP trials consistently show that meaningful weight loss with semaglutide happens gradually over months. In STEP 1, participants lost about 6% of their body weight by week 20 and continued losing until week 68.

If someone genuinely saw a "huge difference" immediately, they should talk to their doctor. Rapid changes could indicate dehydration or other issues that need medical attention.

What did she get right about GLP-1 treatment?

@so.dreamie deserves credit for documenting her journey and being open about using medication for weight management. This kind of transparency helps reduce stigma around obesity treatment.

She's also right that progress tracking can be valuable. The clinical trials for Wegovy included regular monitoring and documentation, which helps both patients and providers assess treatment effectiveness.

Her mention of the "GLP1 community" reflects something positive. Social support can improve treatment adherence, though it's important that online communities don't replace medical supervision.

What should people actually know about starting Wegovy?

Real Wegovy results happen slowly and require patience. The STEP 4 trial (Rubino et al., NEJM, 2021) showed that stopping treatment led to weight regain, which means this isn't a quick fix but a long-term treatment approach.

Side effects are common, especially early in treatment. About 44% of people in STEP 1 experienced nausea, and 24% had diarrhea. Starting at 0.25mg helps minimize these issues.

Most importantly, Wegovy requires medical supervision and isn't appropriate for everyone. It's contraindicated for people with certain thyroid conditions and has specific dosing requirements that need professional oversight.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @so.dreamie's Wegovy first shot documentation, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

Use the health tools and supporting evidence to prepare questions for your clinician.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Claim verdict

The useful answer behind this video

Claim being checked

Wegovy contains semaglutide, a GLP-1 receptor agonist that slows gastric emptying and reduces appetite.

FormBlends verdict

Wegovy contains semaglutide, a GLP-1 receptor agonist that slows gastric emptying and reduces appetite. In the STEP 1 trial, participants lost an average of 14.9% body weight over 68 weeks with the 2.4mg maintenance dose.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Wegovy contains semaglutide, a GLP-1 receptor agonist that slows gastric emptying and reduces appetite. In the STEP 1 trial, participants lost an average of 14.9% body weight over 68 weeks with the 2.4mg maintenance dose.
  • Wegovy's first injection contains 0.25mg semaglutide, designed for tolerability rather than immediate weight loss
  • STEP 1 trial participants lost 14.9% body weight over 68 weeks, not days or weeks

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • Wegovy's first injection contains 0.25mg semaglutide, designed for tolerability rather than immediate weight loss
  • STEP 1 trial participants lost 14.9% body weight over 68 weeks, not days or weeks
  • Meaningful semaglutide weight loss typically begins after reaching higher doses months into treatment
  • About 44% of Wegovy users experience nausea, especially during the initial dose escalation period
  • Documenting treatment progress can be helpful, but dramatic immediate changes warrant medical consultation
  • STEP 4 trial showed weight regain after stopping, indicating Wegovy is a long-term treatment approach
  • All semaglutide treatment requires ongoing medical supervision and isn't appropriate for everyone

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

ShortCakkes · TikTok creator

300.1K views on this video

I found the footage of my taking my first shot of my first box of wegovy! It was on my iPad and I completely forgot that I recorded it on my iPad yall! I defused a huge diffrence yall!! Let me know if

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by ShortCakkes, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.